Bevacizumab-induced proteinuria and its association with antihypertensive drugs: A retrospective cohort study using a Japanese administrative database

Proteinuria is a major side-effect of the anti-tumor drug bevacizumab, although its incidence and risk factors in the real world are still unclear. Although renin-angiotensin-aldosterone system inhibitors are used clinically to prevent proteinuria, their efficacy remains unclear. The aim of the pres...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-08, Vol.18 (8), p.e0289950-e0289950
Main Authors: Kiyomi, Anna, Koizumi, Fukiko, Imai, Shinobu, Yamana, Hayato, Horiguchi, Hiromasa, Fushimi, Kiyohide, Sugiura, Munetoshi
Format: Article
Language:English
Subjects:
Aldosterone
Analysis
Angiotensin
Anticancer properties
Antihypertensive drugs
Antihypertensives
Archives & records
Bevacizumab
Blood pressure
Body mass index
Cancer therapies
Chemotherapy
Clinical trials
Cohort analysis
Colorectal cancer
Confidence intervals
Creatinine
Data analysis
Demographics
Diabetes
Diagnosis
Drug therapy
Drugs
Epidermal growth factor receptors
Evidence-based medicine
Evidence-based nursing
Glomerular filtration rate
Heart failure
Hospital patients
Hospitals
Information management
Kidney cancer
Kidney diseases
Kinases
Laboratories
Laboratory tests
Medical records
Medical research
Medicine and Health Sciences
Medicine, Experimental
Monoclonal antibodies
Nitric oxide
Nurses
Nursing
Ovarian cancer
Patients
Pressure dependence
Proteins
Proteinuria
Regression analysis
Renin
Risk factors
Side effects
Statistical analysis
Targeted cancer therapy
Urine
Vital signs
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proteinuria is a major side-effect of the anti-tumor drug bevacizumab, although its incidence and risk factors in the real world are still unclear. Although renin-angiotensin-aldosterone system inhibitors are used clinically to prevent proteinuria, their efficacy remains unclear. The aim of the present study was to reveal the incidence and risk factors of bevacizumab-induced proteinuria and examine the effectiveness of antihypertensive drugs in preventing proteinuria. We conducted a retrospective cohort study using the National Hospital Organization Clinical Data Archives and Medical Information Analysis Databank. Hospitalized patients who received bevacizumab between January 1, 2016, and June 30, 2019, were included. The study outcome was proteinuria within 12 months of bevacizumab administration. Patient characteristics, laboratory tests, and medications were compared between patients with and without proteinuria using multivariable logistic regression analysis. Among the 2,458 patients, 27% developed proteinuria after bevacizumab administration. Nursing dependence (odds ratio [OR], 2.40; 95% confidence interval [CI], 1.89-3.05; P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0289950